Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05245734
Other study ID # 1901-RH-BF
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date February 8, 2022
Est. completion date April 2025

Study information

Verified date April 2024
Source Biopharma Plasma LLC
Contact Yaroslav Zhebelenko, Ph.D., MD
Phone +380977495979
Email y.zhebelenko@biopharma.ua
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rhesus conflict between mother and fetus is due to the different antigenic composition of erythrocytes. During the first pregnancy, sensitization of the mother to fetal erythrocytes rhesus D (RhD) antigens is formed. During the next pregnancy, fetal red blood cells are attacked by the mother's antibodies, and fetal/newborn hemolytic disease develops. The drug Rhesoglobin blocks the interaction of the fetal erythrocytes RhD antigen and the immune system of the mother and prevents the development of Rhesus sensitization.


Description:

The screening stage The pregnant woman (participant) has to sign an informed consent. After the signed informed consent procedure, the patient is assessed for meeting the inclusion and non-inclusion (exclusion) criteria. Patients who were included in the study are assessed according to additional criteria for inclusion in the "Pharmacokinetics" subgroup. The clinical stage According to the study protocol, patients receive two prophylactic doses of the study drug at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery. Patients receive the second dose only in the case of the birth of an Rh-positive child. Before and after each injection of the drug, blood will be taken to control the level of anti-Rh0 (D) antibodies. In the "Pharmacokinetics" subgroup, additional blood samples will be taken to determine the following pharmacokinetic parameters: - Serum clearance - Volume of distribution - AUC (area under curve) - Т1/2 (α and β) (half-life time) - Cmax (maximum/peak serum concentration) - Tmax (time to reach the maximum serum concentration) - Kel (elimination rate constant) The final stage The patient should be monitored for 6 months ± 5 days, after the last injection of the drug, blood samples are taken after 3 and 6 months to assess sensitization to the Rh antigen.


Recruitment information / eligibility

Status Recruiting
Enrollment 281
Est. completion date April 2025
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Rh-negative women who are not sensitized to Rh0 (D) antigen between the ages of 18 and 45; - signed informed patient consent to participate in the study; - pregnancy from a Rh-positive man; - immunocompetent patients (CD 4+ counts above 200 per µl, HIV negative, or those with the virus particle count of less than 200 per µl or 400000 per ml); - body mass index should be within normal limits (> 18.5 kg / m2 and <30.0 kg / m2); - patients who have not received blood transfusions and / or medicinal products containing immunoglobulins in the last 6 months, in particular antibodies to Rh0 (D) antigen; - persons who do not have acute and chronic cardiovascular, neuroendocrine, kidney, liver diseases, diseases of gastrointestinal tract, respiratory system; - the results of physical, instrumental and laboratory examination of patients should be within the norma or deviations should be regarded by the researcher as clinically insignificant; - the ability, according to the researcher, to comply with all the requirements of the study protocol. Exclusion Criteria: - sensitization to Rh0 (D) antigen; - the absence of reliable anamnestic data on the prevention of Rh incompatibility in previous pregnancy (s) with the birth of a Rh-positive child; - selective IgA deficiency in the presence of antibodies against immunoglobulin A (IgA); - history of severe allergic reactions to the administration of human blood protein preparations; - hypersensitivity reactions to human donor immunoglobulins; - severe thrombocytopenia and other hemostatic disorders; - life-threatening conditions and / or complications that require intensive care / surgery, the presence of any other bleeding at the time of screening; - Rh-negative fetus; - any other concomitant decompensated diseases or acute conditions, the presence of which, according to the researcher, can significantly affect the study results; - participation in any other clinical trial in the last 3 months and throughout the study. Additional exclusion criteria: Subgroup "Pharmacokinetics" (patients included in the additional study of some pharmacokinetic parameters): - any previous disease or intervention that, according to the researcher, may affect the pharmacokinetics of the study drug, in particular, organ and bone marrow transplantation, cancers; - presence of HIV, hepatitis B, or C viruses; - presence of severe clinical and laboratory manifestations of impaired liver and kidney function

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Human Anti-D (rh) immunoglobulin
prevention of Rh-sensitization in pregnant women in the antenatal and postnatal period in routine clinical practice. The study drug is administered twice at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery.

Locations

Country Name City State
Ukraine Municipal non-profit enterprise "Cherkasy Regional Hospital of Cherkasy Regional Council" Cherkasy Cherkasy Region
Ukraine Municipal non-profit enterprise "Maternity hospital" of the Chernihiv city council Chernihiv
Ukraine Municipal non-profit enterprise "Chernivtsi Regional Perinatal Center" Chernivtsi
Ukraine Municipal enterprise "Dnipropetrovsk Regional Perinatal Center (DRPC) with a hospital" of the Dnipropetrovsk Regional Council Dnipro
Ukraine Municipal non-profit enterprise "Ivano-Frankivsk Regional Perinatal Center Ivano-Frankivsk Regional Council" Ivano-Frankivsk
Ukraine Municipal non-profit enterprise "Khmelnytsky Regional Hospital" of the Khmelnytsky Regional Council Khmelnytskyi
Ukraine Municipal non-profit enterprise "Kirovohrad Regional Hospital of the Kirovohrad Regional Council" Kropyvnytskyi
Ukraine Kyiv City Center for Reproductive and Perinatal Medicine Kyiv
Ukraine State Institution "Institute of Pediatrics, Obstetrics and Gynecology named after academician O.M. Lukyanova National Academy of Medical Sciences of Ukraine " Kyiv
Ukraine Municipal enterprise "Volyn Regional Territorial Medical Association for the Protection of Motherhood and Childhood" Volyn Regional Council Luts'k
Ukraine Municipal non-profit enterprise Lviv Regional Council "Lviv Regional Clinical Perinatal Center" Lviv
Ukraine Municipal non-profit enterprise "Mykolayiv regional clinical hospital" of the Mykolayiv regional council Mykolayiv
Ukraine Municipal enterprise "Poltava Regional Clinical Hospital named after M.V. Sklifosovsky Poltava regional council" Poltava
Ukraine Municipal Institution "Regional Perinatal Center" of Rivne Regional Council Rivne
Ukraine Municipal non-profit enterprise Sumy regional council "Regional Clinical Perinatal Center" Sumy
Ukraine Municipal non-profit enterprise "Maternity hospital ?3" of Zaporizhia City Council Zaporizhzhia

Sponsors (3)

Lead Sponsor Collaborator
Biopharma Plasma LLC Ivano-Frankivsk National Medical University, State Institution, Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine

Country where clinical trial is conducted

Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Other Serum clearance Pharmacokinetic parameter are determined after first administration of the study drug 3 months after first administration of the study drug
Other volume of distribution Pharmacokinetic parameter are determined after first administration of the study drug 3 months after first administration of the study drug
Other Area under the curve (AUC) Pharmacokinetic parameter are determined after first administration of the study drug 3 months after first administration of the study drug
Other Half-life time (T1/2 a and ß) Pharmacokinetic parameter are determined after first administration of the study drug 3 months after first administration of the study drug
Other Maximum/peak serum concentration (Cmax) Pharmacokinetic parameter are determined after first administration of the study drug 3 months after first administration of the study drug
Other Time to reach the maximum serum concentration (Tmax) Pharmacokinetic parameter are determined after first administration of the study drug 3 months after first administration of the study drug
Other Elimination rate constant (Kel) Pharmacokinetic parameter are determined after first administration of the study drug 3 months after first administration of the study drug
Primary The part of patients with no antibodies to Rh0 (D) antigen The proportion of patients with no antibodies to Rh0 (D) antigen 6 months after the last administration of the drug 6 months after the last administration of the drug
Secondary Titer of anti-Rh0 (D) antibodies Titer of anti-Rh0 (D) antibodies 3 months after delivery 3 months after delivery
Secondary Titer of anti-Rh0 (D) antibodies Titer of anti-Rh0 (D) antibodies 6 months after delivery 6 months after delivery
Secondary The part of patients with no antibodies to Rh0 (D) antigen 3 months after delivery Proportion of patients with no antibodies to Rh0 (D) antigen 3 months after the last administration of the drug 3 months after the last administration of the drug
Secondary Proportion of patients who developed adverse events and reactions (AE / AR) Proportion of patients who developed adverse events and reactions (AE / AR) associated with the administration of the drug, stratified by severity 9 months from the first administration of the drug
See also
  Status Clinical Trial Phase
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT06258902 - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed NCT05487196 - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia Phase 2
Completed NCT03750968 - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects Phase 2
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT06069869 - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06069856 - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Not yet recruiting NCT06079918 - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania Phase 3